Mr. Pettitt holds a MS with concentrations in immunology and virology from Hood College.
He is the efficacy lead in the Mapp Biopharmaceutical nonclinical group focusing on late stage products under the FDA Animal Rule.
Programs currently include countermeasures against Marburg virus, Sudan virus, Nipah virus, and Botulinum toxins.
Previously, Mr. Pettitt worked on early monoclonal cocktail development against Ebola virus at the United States Army Research Institute of Infectious Diseases (USAMRIID).
He continued this work at the National Institute of Allergy and Infectious Diseases Integrated Research Facility (NIAID IRF), utilizing novel imaging technologies within BSL4 containment.
Additionally, he has overseas experience in Republic of Georgia and Mongolia for CCHF and MERS, as well as serving as Scientific Lead on outbreak response teams to West Africa during the 2014-2016 Ebola pandemic.
He has been awarded the NIH Director’s Award (2015) and the NIAID Merit Award (2017) for these efforts.